Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Once disseminated disease is excluded, histologically confirmed HIV-positive patients with
localized Kaposi's sarcoma of the airway will be randomized to receive HAART only or HAART +
The primary outcome will be the size of lesions according to RECIST criteria. Patients in
the HAART + bevacizumab arm will undergo series of 3 bevacizumab injections of 5 mg/cm3.
Follow-up will be carried out through scheduled meetings for office setting examination
every week for the first 8 weeks, then every 15 days for two months and finally every month
for eight months.
Size of the lesions will be assessed by an independent observer and adverse events will be
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Size of lesions
Size of lesions will be assessed according to RECIST criteria
Gustavo Reyes-Teran, M.D.
Centro de Investigacion en Enfermedades Infecciosas
Mexico: Ethics Committee